CeriBell (CBLL) Stock Analysis & AI Equity Report
CeriBell (CBLL) overview
CeriBell (CBLL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 89.1m and operating profit of USD -58.4m; the year-end share price was 21.93 USD and market capitalisation was USD 822m. CeriBell is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CeriBell's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About CeriBell
CeriBell is a medical technology company offering the Ceribell System, a portable point-of-care EEG platform for acute care settings. The system combines rapidly deployable hardware with AI-powered algorithms to support diagnosis and continuous monitoring of patients with neurological conditions, particularly seizure detection and management. Its users include hospitals and clinicians caring for patients at risk of seizures.
Generate the CeriBell report
CeriBell is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CeriBell and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on CeriBell
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.